Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 168.72Kに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 348.06です。
割高
同社の最新のPEは-1.23で、過去3年間の水準と比較して高値圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は2.88M株で、前四半期比で10.83%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を159.88K株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は1.05です。